Pharmacokinetics, immunogenicity and clinical outcomes of golimumab from the PURSUIT PEDS ulcerative colitis study long-term (through week 126) extension

被引：0
|
作者：
Hyams, J. [1 ]
O'Brien, C. D. [2 ]
Padgett, L. [2 ]
Rosh, J. [3 ]
Turner, D. [4 ]
Veereman, G. [5 ]
Griffiths, A. [6 ]
Heyman, M. B. [7 ]
Wahbeh, G. [8 ]
Adedokun, J. [2 ]
Strauss, R. [2 ]
Chan, D. [2 ]
Lynch, J. [2 ]
机构：
[1] Connecticut Childrens Med Ctr, Hartford, CT USA
[2] Janssen Res & Dev LLC, Spring House, PA USA
[3] Goryeb Childrens Hosp, Atlantic Hlth, Pediat Gastroenterol Clin Dev & Res Affairs, Morristown, NJ USA
[4] Shaare Zedek Med Ctr, Juliet Keidan Inst Pediat Gastroenterol & Nutr, Jerusalem, Israel
[5] Free Univ Brussels, Brussels, Belgium
[6] Univ Toronto, Hosp Sick Children, Toronto, ON, Canada
[7] Univ Calif San Francisco, Div Gastroenterol, San Francisco, CA 94143 USA
[8] Seattle Childrens Hosp, Seattle, WA USA
来源：
JOURNAL OF CROHNS & COLITIS | 2018年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P396
引用
收藏
页码：S304 / S305
页数：2
相关论文
共 50 条
  • [1] Safety, efficacy, and pharmacokinetics of golimumab in patients with moderately to severely Active ulcerative colitis: PURSUIT-SC long-term extension
    Reinisch, W.
    Gibson, P.
    Sandborn, W. J.
    Feagan, B.
    Marano, C.
    Strauss, R.
    Johanns, J.
    Zhang, H.
    Padgett, L.
    Adedokun, O. J.
    Colombel, J. -F.
    Collins, J.
    Rutgeerts, P.
    Tarabar, D.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S248 - S249
  • [2] Safety, Efficacy, and Pharmacokinetics of Golimumab in Patients with Moderately to Severely Active Ulcerative Colitis: PURSUIT-SC Long term Extension
    Reinisch, Walter
    Gibson, Peter R.
    Sandborn, William
    Feagan, Brian G.
    Marano, Colleen
    Strauss, Rick
    Johanns, Jewel
    Zhang, Hongyan
    Padgett, Lakshmi
    Adedokun, Omoniyi J.
    Colombel, Jean-Frederic
    Collins, Judith
    Rutgeerts, Paul J.
    Tarabar, Dino
    GASTROENTEROLOGY, 2016, 150 (04) : S776 - S777
  • [3] Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension
    Reinisch, Walter
    Gibson, Peter R.
    Sandborn, William J.
    Feagan, Brian G.
    Strauss, Richard
    Johanns, Jewel
    Padgett, Lakshmi
    Adedokun, Omoniyi J.
    Colombel, Jean-Frederic
    Collins, Judith
    Rutgeerts, Paul
    Tarabar, Dino
    Marano, Colleen
    JOURNAL OF CROHNS & COLITIS, 2018, 12 (09): : 1053 - 1066
  • [4] Long-term safety and efficacy of golimumab in patients with moderately to severely active ulcerative colitis: Results from the PURSUIT-SC Maintenance study extension
    Reinisch, W.
    Gibson, P.
    Sandborn, W. J.
    Feagan, B. G.
    Marano, C.
    Strauss, R.
    Johanns, J.
    Zhang, H.
    Padgett, L.
    Colombel, J. -F.
    Collins, J.
    Rutgeerts, P.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S6 - S7
  • [5] Long-Term Safety and Efficacy of Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the PURSUIT-SC Maintenance Study Extension
    Gibson, Peter R.
    Reinisch, Walter
    Sandborn, William
    Feagan, Brian G.
    Marano, Colleen W.
    Strauss, Richard
    Johanns, Jewel
    Zhang, Hongyan
    Padgett, Lakshmi
    Colombel, Jean-Frederic
    Collins, Judith
    Rutgeerts, Paul J.
    GASTROENTEROLOGY, 2014, 146 (05) : S587 - S587
  • [6] Efficacy of ustekinumab for Ulcerative Colitis through 4 years: Final clinical and endoscopy outcomes from the UNIFI long-term extension
    Danese, S.
    Afif, W.
    Abreu, M.
    Sandborn, W.
    Miao, Y.
    Zhang, H.
    Panaccione, R.
    Hisamatsu, T.
    Scherl, E.
    Leong, R.
    Rowbotham, D.
    Arasaradnam, R.
    Peyrin-Biroulet, L.
    Sands, B.
    Marano, C.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : I19 - I20
  • [7] Efficacy of ustekinumab for ulcerative colitis through 4 years: Final clinical and endoscopy outcomes from the UNIFI long-term extension
    Danese, S.
    Afif, W.
    Abreu, M. T.
    Sandborn, W. J.
    Miao, Y.
    Zhang, H.
    Panaccione, R.
    Hisamatsu, T.
    Scherl, E. J.
    Leong, R.
    Rowbotham, D. S.
    Arasaradnam, R. P.
    Peyrin-Biroulet, L.
    Sands, B. E.
    Marano, C.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 117 - 118
  • [8] EFFICACY OF USTEKINUMAB FOR ULCERATIVE COLITIS THROUGH 4 YEARS: FINAL CLINICAL AND ENDOSCOPY OUTCOMES FROM THE UNIFI LONG-TERM EXTENSION
    Peyrin-Biroulet, Laurent
    Afif, Waqqas
    Abreu, Maria T.
    Danese, Silvio
    Sandborn, William J.
    Miao, Ye
    Zhang, Hongyan
    Panaccione, Remo
    Hisamatsu, Tadakazu
    Scherl, Ellen J.
    Leong, Rupert
    Rowbotham, David S.
    Arasaradnam, Ramesh P.
    Sands, Bruce E.
    Marano, Colleen W.
    GASTROENTEROLOGY, 2023, 164 (06) : S1094 - S1094
  • [9] Low occurrence of colectomy with long-term (up to 4 years) golimumab treatment in patients with moderate-to-severe active Ulcerative Colitis: Data from the PURSUIT maintenance and long-term extension studies
    Weinstein, C. L.
    Meehan, A. G.
    Lin, J.
    Govoni, M.
    Qureshi, Z. P.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I114 - I115
  • [10] Low Occurrence of Colectomy With Long-Term (up to 4 Years) Golimumab Treatment in Patients With Moderate-to-Severe Active Ulcerative Colitis: Data From the PURSUIT Maintenance and Long-Term Extension Studies
    Weinstein, Cindy L. J.
    Meehan, Alan G.
    Govoni, Marinella
    Lin, Jianxin
    Reinisch, Walter
    CROHNS & COLITIS 360, 2023, 5 (03)
12345